Lipid-Mediated Cell Surface Engineering

Micro-and Nanoengineering of the Cell Surface

Volumn , Issue , 2014, Pages 121-141

  Patel, Jaina M ^a   Vartabedian, Vincent F ^a   Selvaraj, Periasamy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccines; Cholesterol anchors; Glycosyl phosphatidylinositol (GPI) anchor; Palmitoylated protein A G and tethered ligands

Indexed keywords

CELL MEMBRANES; CELLS; CYTOLOGY; ENZYME ACTIVITY; LIPID BILAYERS; PROTEINS; TARGETED DRUG DELIVERY; VACCINES;

ANTIGEN PRESENTING CELLS; CANCER VACCINE; CELL SURFACE ENGINEERING; FUNCTIONAL PROTEINS; INCORPORATION METHOD; INTRACELLULAR SPACES; PHOSPHATIDYLINOSITOL; TETHERED LIGAND;

CELL ENGINEERING;

EID: 84931030074     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-3146-6.00006-4     Document Type: Chapter

References (90)

1. The tercentenary of Robert Hooke. Can Med Assoc J 1935;33(3):312-13.
2. Singer S.J., Nicolson G.L. The fluid mosaic model of the structure of cell membranes. Science 1972, 175(4023):720-731.
3. Brown D.A., Rose J.K. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 1992, 68(3):533-544.
4. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387(6633):569-572.
5. Wenz J.J., Barrantes F.J. Steroid structural requirements for stabilizing or disrupting lipid domains. Biochemistry 2003, 42(48):14267-14276.
6. Ishitsuka R., Sato S.B., Kobayashi T. Imaging lipid rafts. J Biochem 2005, 137(3):249-254.
7. Kooyman D.L., Byrne G.W., Logan J.S. Glycosyl phosphatidylinositol anchor. Exp Nephrol 1998, 6(2):148-151.
8. Legler D.F., Doucey M.A., Schneider P., Chapatte L., Bender F.C., Bron C. Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. FASEB J 2005, 19(1):73-75.
9. Xu X., London E. The effect of sterol structure on membrane lipid domains reveals how cholesterol can induce lipid domain formation. Biochemistry 2000, 39(5):843-849.
10. Bruckdorfer K.R., Edwards P.A., Green C. Properties of aqueous dispersions of phospholipid and cholesterol. Eur J Biochem 1968, 4(4):506-511.
11. Bruckdorfer K.R., Graham J.M., Green C. The incorporation of steroid molecules into lecithin sols, beta-lipoproteins and cellular membranes. Eur J Biochem 1968, 4(4):512-518.
12. Cooper R.A., Arner E.C., Wiley J.S., Shattil S.J. Modification of red cell membrane structure by cholesterol-rich lipid dispersions. A model for the primary spur cell defect. J Clin Invest 1975, 55(1):115-126.
13. Martin S.E., Peterson B.R. Non-natural cell surface receptors: synthetic peptides capped with N-cholesterylglycine efficiently deliver proteins into mammalian cells. Bioconjug Chem 2003, 14(1):67-74.
14. Kan C.C., Yan J., Bittman R. Rates of spontaneous exchange of synthetic radiolabeled sterols between lipid vesicles. Biochemistry 1992, 31(6):1866-1874.
15. Hussey S.L., He E., Peterson B.R. A synthetic membrane-anchored antigen efficiently promotes uptake of antifluorescein antibodies and associated protein a by mammalian cells. J Am Chem Soc 2001, 123(50):12712-12713.
16. Hussey S.L., Peterson B.R. Efficient delivery of streptavidin to mammalian cells: clathrin-mediated endocytosis regulated by a synthetic ligand. J Am Chem Soc 2002, 124(22):6265-6273.
17. Dunphy J.T., Linder M.E. Signalling functions of protein palmitoylation. Biochim Biophys Acta 1998, 1436(1-2):245-261.
18. Ross E.M. Protein modification. Palmitoylation in G-protein signaling pathways. Curr Biol 1995, 5(2):107-109.
19. Duncan J.A., Gilman A.G. Autoacylation of G protein alpha subunits. J Biol Chem 1996, 271(38):23594-23600.
20. Peacock J.S., Londo T.R., Roess D.A., Barisas B.G. Biologic activity of antigen receptors artificially incorporated onto B lymphocytes. J Immunol 1986, 137(6):1916-1923.
21. Cheung K.K., Newton A. Patterns of protein synthesis during development in Caulobacter crescentus. Dev Biol 1977, 56(2):417-425.
22. Chou S.H., Shetty A.V., Geng Y., Xu L., Munirathinam G., Pipathsouk A., et al. Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity. Cancer Immunol Immunother 2013, 62(3):597-603.
23. Londo T.R., Peacock J.S., Roess D.A., Barisas B.G. Lateral diffusion of antigen receptors artificially incorporated onto B lymphocytes. J Immunol 1986, 137(6):1924-1931.
24. Colsky A.S., Stein-Streilein J., Peacock J.S. Surrogate receptor-mediated cellular cytotoxicity. A method for "custom designing" killer cells of desired target specificity. J Immunol 1988, 140(8):2515-2519.
25. Colsky A.S., Peacock J.S. Palmitate-derivatized antibodies can function as surrogate receptors for mediating specific cell-cell interactions. J Immunol Methods 1989, 124(2):179-187.
26. Elortza F., Mohammed S., Bunkenborg J., Foster L.J., Nuhse T.S., Brodbeck U., et al. Modification-specific proteomics of plasma membrane proteins: identification and characterization of glycosylphosphatidylinositol-anchored proteins released upon phospholipase D treatment. J Proteome Res 2006, 5(4):935-943.
27. Maeda Y., Kinoshita T. Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. Prog Lipid Res 2011, 50(4):411-424.
28. Loizides-Mangold U., David F.P., Nesatyy V.J., Kinoshita T., Riezman H. Glycosylphosphatidylinositol anchors regulate glycosphingolipid levels. J Lipid Res 2012, 53(8):1522-1534.
29. Ikezawa H., Yamanegi M., Taguchi R., Miyashita T., Ohyabu T. Studies on phosphatidylinositol phosphodiesterase (phospholipase C type) of Bacillus cereus. I. purification, properties and phosphatase-releasing activity. Biochim Biophys Acta 1976, 450(2):154-164.
30. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 1981, 256(4):1604-1607.
31. Roberts W.L., Myher J.J., Kuksis A., Low M.G., Rosenberry T.L. Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. Palmitoylation of inositol results in resistance to phosphatidylinositol-specific phospholipase C. J Biol Chem 1988, 263(35):18766-18775.
32. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984, 160(5):1558-1578.
33. Medof M.E., Gottlieb A., Kinoshita T., Hall S., Silber R., Nussenzweig V., et al. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest 1987, 80(1):165-174.
34. Zalman L.S., Wood L.M., Frank M.M., Muller-Eberhard H.J. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med 1987, 165(2):572-577.
35. Sugita Y., Nakano Y., Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 1988, 104(4):633-637.
36. Davies A., Simmons D.L., Hale G., Harrison R.A., Tighe H., Lachmann P.J., et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989, 170(3):637-654.
37. Holguin M.H., Fredrick L.R., Bernshaw N.J., Wilcox L.A., Parker C.J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989, 84(1):7-17.
38. Seifert P.S., Roth I., Schmiedt W., Oelert H., Okada N., Okada H., et al. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis 1992, 96(2-3):135-145.
39. Wing M.G., Zajicek J., Seilly D.J., Compston D.A., Lachmann P.J. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology 1992, 76(1):140-145.
40. Hansch G.M., Schonermark S., Roelcke D. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest 1987, 80(1):7-12.
41. Selvaraj P., Dustin M.L., Silber R., Low M.G., Springer T.A. Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med 1987, 166(4):1011-1025.
42. Dustin M.L., Selvaraj P., Mattaliano R.J., Springer T.A. Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature 1987, 329(6142):846-848.
43. Selvaraj P., Plunkett M.L., Dustin M., Sanders M.E., Shaw S., Springer T.A. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987, 326(6111):400-403.
44. Nagarajan S., Anderson M., Ahmed S.N., Sell K.W., Selvaraj P. Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fc gamma receptor III. J Immunol Methods 1995, 184(2):241-251.
45. Zhang F., Schmidt W.G., Hou Y., Williams A.F., Jacobson K. Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes. Proc Natl Acad Sci USA 1992, 89(12):5231-5235.
46. Bulow R., Overath P., Davoust J. Rapid lateral diffusion of the variant surface glycoprotein in the coat of Trypanosoma brucei. Biochemistry 1988, 27(7):2384-2388.
47. Poloso N.J., Nagarajan S., Bumgarner G.W., Selvaraj P. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 2001, 19(15-16):2029-2038.
48. McHugh R.S., Ahmed S.N., Wang Y.C., Sell K.W., Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995, 92(17):8059-8063.
49. Los D.A., Murata N. Membrane fluidity and its roles in the perception of environmental signals. Biochim Biophys Acta 2004, 1666(1-2):142-157.
50. Premkumar D.R., Fukuoka Y., Sevlever D., Brunschwig E., Rosenberry T.L., Tykocinski M.L., et al. Properties of exogenously added GPI-anchored proteins following their incorporation into cells. J Cell Biochem 2001, 82(2):234-245.
51. 2+-signaling competent. J Cell Biol 1995, 131(3):669-677.
52. McHugh R.S., Nagarajan S., Wang Y.C., Sell K.W., Selvaraj P. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999, 59(10):2433-2437.
53. Poloso N.J., Nagarajan S., Mejia-Oneta J.M., Selvaraj P. GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol Immunol 2002, 38(11):803-816.
54. Nagarajan S., Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002, 62(10):2869-2874.
55. Bozeman E.N., Cimino-Mathews A., Machiah D.K., Patel J.M., Krishnamoorthy A., Tien L., et al. Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine 2013, 31(20):2449-2456.
56. Brunschwig E.B., Levine E., Trefzer U., Tykocinski M.L. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995, 155(12):5498-5505.
57. Nagarajan S., Selvaraj P. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Vaccine 2006, 24(13):2264-2274.
58. Brunschwig E.B., Fayen J.D., Medof M.E., Tykocinski M.L. Protein transfer of glycosyl-phosphatidylinositol (GPI)-modified murine B7-1 and B7-2 costimulators. J Immunother 1999, 22(5):390-400.
59. Chesla S.E., Li P., Nagarajan S., Selvaraj P., Zhu C. The membrane anchor influences ligand binding two-dimensional kinetic rates and three-dimensional affinity of FcgammaRIII (CD16). J Biol Chem 2000, 275(14):10235-10246.
60. Barboni E., Rivero B.P., George A.J., Martin S.R., Renoup D.V., Hounsell E.F., et al. The glycophosphatidylinositol anchor affects the conformation of Thy-1 protein. J Cell Sci 1995, 108(Pt 2):487-497.
61. Butikofer P., Malherbe T., Boschung M., Roditi I. GPI-anchored proteins: now you see 'em, now you don't. FASEB J 2001, 15(2):545-548.
62. Paulick M.G., Bertozzi C.R. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 2008, 47(27):6991-7000.
63. Lehto M.T., Sharom F.J. Proximity of the protein moiety of a GPI-anchored protein to the membrane surface: a FRET study. Biochemistry 2002, 41(26):8368-8376.
64. Huang J.H., Getty R.R., Chisari F.V., Fowler P., Greenspan N.S., Tykocinski M.L. Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1994, 1(7):607-613.
65. Lotze M.T., Chang A.E., Seipp C.A., Simpson C., Vetto J.T., Rosenberg S.A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 1986, 256(22):3117-3124.
66. Wahlsten J.L., Mills C.D., Ramakrishnan S. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol 1998, 161(12):6761-6767.
67. Englund P.T. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem 1993, 62:121-138.
68. Diamandis E.P., Christopoulos T.K. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 1991, 37(5):625-636.
69. Lindqvist Y., Schneider G. Protein-biotin interactions. Curr Opin Struct Biol 1996, 6(6):798-803.
70. Singh N.P., Yolcu E.S., Askenasy N., Shirwan H. ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation. Ann NY Acad Sci 2005, 1056:344-358.
71. Green N.M. Avidin and streptavidin. Methods Enzymol 1990, 184:51-67.
72. Yolcu E.S., Askenasy N., Singh N.P., Cherradi S.E., Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002, 17(6):795-808.
73. Singh N.P., Yolcu E.S., Taylor D.D., Gercel-Taylor C., Metzinger D.S., Dreisbach S.K., et al. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res 2003, 63(14):4067-4073.
74. Askenasy E.M., Shushlav Y., Sun Z., Shirwan H., Yolcu E.S., Askenasy N. Engineering of bone marrow cells with fas-ligand protein-enhances donor-specific tolerance to solid organs. Transplant Proc 2011, 43(9):3545-3548.
75. Kaminitz A., Yolcu E.S., Stein J., Yaniv I., Shirwan H., Askenasy N. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun 2011, 37(1):39-47.
76. Kaminitz A., Askenasy N., Yolcu E.S. Immunomodulation with regulatory T cells and Fas-ligand ameliorate established inflammatory colitis. Gut 2013, 62(8):1228-1230.
77. Yolcu E.S., Kaminitz A., Mizrahi K., Ash S., Yaniv I., Stein J., et al. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease. Exp Hematol 2013.
78. Kim S.A., Peacock J.S. The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions. J Immunol Methods 1993, 158(1):57-65.
79. Kronvall G., Grey H.M., Williams R.C. Protein A reactivity with mouse immunoglobulins. Structural relationship between some mouse and human immunoglobulins. J Immunol 1970, 105(5):1116-1123.
80. Kronvall G., Messner R.P., Williams R.C. Immunochemical studies on the interaction between staphylococcal protein A and gamma-G globulin. J Immunol 1970, 105(6):1353-1359.
81. Chen A., Zheng G., Tykocinski M.L. Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. J Immunol 2000, 164(2):705-711.
82. Zheng G., Chen A., Sterner R.E., Zhang P.J., Pan T., Kiyatkin N., et al. Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer. Cancer Res 2001, 61(22):8127-8134.
83. Zheng G., Liu S., Wang P., Xu Y., Chen A. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells. Cancer Res 2006, 66(13):6793-6799.
84. van Broekhoven C.L., Parish C.R., Vassiliou G., Altin J.G. Engrafting costimulator molecules onto tumor cell surfaces with chelator lipids: a potentially convenient approach in cancer vaccine development. J Immunol 2000, 164(5):2433-2443.
85. van Broekhoven C.L., Parish C.R., Demangel C., Britton W.J., Altin J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004, 64(12):4357-4365.
86. Faham A., Herringson T., Parish C., Suhrbier A., Khromykh A.A., Altin J.G. pDNA-lipoplexes engrafted with flagellin-related peptide induce potent immunity and anti-tumour effects. Vaccine 2011, 29(40):6911-6919.
87. Herringson T.P., Altin J.G. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Int J Pharm 2011, 411(1-2):206-214.
88. Herringson T.P., Patlolla R.R., Altin J.G. Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J Gene Med 2009, 11(11):1048-1063.
89. Herringson T.P., Altin J.G. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid. J Drug Target 2011, 19(8):681-689.
90. Van Broekhoven C.L., Altin J.G. A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol Cell Biol 2001, 79(3):274-284.